SAN DIEGO, April 24, 2012 /PRNewswire/ -- Verenium Corporation (Nasdaq: VRNM), a leading industrial biotechnology company focused on the development and commercialization of high-performance enzymes, today announced that the Company is a sponsor and scheduled presenter at the upcoming 2012 BIO World Congress on Industrial Biotechnology and Bioprocessing. The conference is taking place April 29 - May 2, 2012 at the Gaylord Palms Resort and Convention Center in Orlando, Florida.
James Levine, President and Chief Executive Officer, will make opening remarks at a plenary luncheon hosted by the Company, The Future of Biocatalysis in Global Manufacturing on Tuesday, May 1st at 12:00 pm EDT.
Mr. Levine will also be speaking on a panel, Financing Innovation in the Industrial Biotech Space: Creative Models and Future Trends on Wednesday, May 2nd at 8:00 am EDT.
Verenium will also have an exhibitor booth (#212) in the Gaylord Palms Resort and Convention Center.
For more information on the BIO World Congress on Industrial Biotechnology and Bioprocessing visit http://www.bio.org/events/conferences/welcome-2012-bio-world-congress.
Verenium, an industrial biotechnology company, is a global leader in developing high-performance enzymes. Verenium's tailored enzymes are environmentally friendly, making products and processes greener and more cost-effective for industries, including the global food and fuel markets. Read more at www.verenium.com.
Statements in this press release that are not strictly historical are "forward-looking" and involve a high degree of risk and uncertainty. These include, but are not limited to, statements related to Verenium's technology, products and product candidates, lines of business, operations, capabilities, commercialization activities, corporate partnerships, target markets, future financial performance, and near-term and longer-term growth and prospects. Such statements are only predictions, and actual events or results may differ materially from those projected in such forward-looking statements. Factors that could cause or contribute to the differences include, but are not limited to, risks associated with Verenium's strategic focus, technologies, products and product candidates, dependence on patents and proprietary rights, protection and enforcement of its patents and proprietary rights, the commercial prospects of the industries in which Verenium operates and sells products, Verenium's dependence on manufacturing and/or license agreements, its ability to achieve milestones under existing and future collaboration agreements, the ability of Verenium and its partners to commercialize its technologies and products (including by obtaining any required regulatory approvals) using Verenium's technologies, the timing for launching any commercial products and projects, the ability of Verenium and its collaborators to market and sell any products that it or they commercialize, the development or availability of competitive products or technologies, the future ability of Verenium to enter into and/or maintain collaboration and joint venture agreements and licenses, and risks and other uncertainties more fully described in Verenium's filings with the Securities and Exchange Commission, including, but not limited to, Verenium's annual report on Form 10-K for the year ended December 31, 2011 and any updates contained in its subsequently filed quarterly reports on Form 10-Q. These forward-looking statements speak only as of the date hereof, and Verenium expressly disclaims any intent or obligation to update these forward-looking statements.
Manager, Corporate Communications
SOURCE Verenium Corporation